ArticleACS pharmacology & translational science2025
Design and Synthesis of Novel Pirfenidone Analogues for Targeting Fibroblast Differentiation via Transforming Growth Factor-β/Smad Pathway Using
Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treatment of pulmonary fibrosis: From disease mechanisms to future novel therapies (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary fibrosis is a progressive interstitial lung disease characterized by excessive extracellular matrix (ECM) deposition, resulting in impaired respiratory function. Due to the limited efficacy of current antifibrotic therapies, there is an urgent need to develop novel agents or optimize existing drugs. In this study, a series of pirfenidone (PFD) derivatives were rationally designed and synthesized with targeted modifications at the third position of the core scaffold to enhance antifibrotic efficacy. A total of 30 derivatives (100 μM) were screened using a TGF-β-induced differentiation model, leading to the identification of hit compounds with superior activity compared to PFD (500 μM). Selected candidates were further validated both in vitro (LL29 and DHLF cells) and in the bleomycin (BLMN)-induced pulmonary fibrosis mouse model. In vitro, compounds
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.